Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
Elevai Labs established two subsidiaries: Elevai Biosciences, Inc., and Elevai Skincare, Inc. Elevai Biosciences will focus on acquiring and developing biopharmaceutical technologies with initial focus on the development of EL-22 and EL-32, the lead assets targeting indications associated with obesity. Elevai Skincare will continue commercializing exosome skincare technologies for the medical dispensed skincare market. NEWPORT BEACH, Calif., May 01, 2024 (GLOBE NEWSWIRE) — Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced the establishment of two new wholly owned subsidiaries, Elevai Biosciences, Inc., and Elevai Skincare, Inc. These ventures mark a strategic shift towards the development of next-generation aesthetic medicines and efforts to improve the economics of its commercialized exosome skincare brand.